Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
September 7, 2017
Rockwell Medical Appoints John G. Cooper to Board of Directors
WIXOM, Mich., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease ...
September 6, 2017
CytoSorbents to Present at the 2017 Rodman & Renshaw Annual Global Investment Conference
MONMOUTH JUNCTION, N.J., Sept. 6, 2017 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb®blood filter to prevent or treat deadly ...
September 6, 2017
Aeglea BioTherapeutics Doses Two Patients in Repeat Dose Part of Phase 1/2 Clinical Trial for the Treatment of Arginase 1 Deficiency
AUSTIN, Texas, Sept. 06, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino ...
September 6, 2017
Palatin Technologies Announces Signing of Licensing Agreement with Fosun Pharma Rights to Bremelanotide in China and Other Selected Territories
CRANBURY, NJ, Sept. 6, 2017 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN; "Palatin") announced today that it has entered into a collaboration and license agreement ...
September 6, 2017
MediWound’s NexoBrid® Highlighted in 43 Presentations at the 17th European Burns Association Congress
YAVNE, Israel, Sept. 06, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe ...
September 6, 2017
Ignyta Provides Regulatory Update on Entrectinib ROS1 Lung Cancer Development Program
SAN DIEGO -- (BUSINESS WIRE) -- Ignyta, Inc. (RXDX), a biotechnology company focused on precision medicine in oncology, today announced that, based on recent FDA guidance, Ignyta has ...
September 6, 2017
HTG Molecular Diagnostics to Present at the Rodman & Renshaw 19th Annual Investment Conference
TUCSON, Ariz., Sept. 06, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (HTGM), a provider of instruments, reagents and services for molecular profiling applications, today ...
September 6, 2017
Aimmune Therapeutics to Participate in Three Investor Conferences in September
BRISBANE, Calif. -- (BUSINESS WIRE) -- Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune ...
September 6, 2017
Altimmune to Provide Corporate Update at the Rodman & Renshaw Global Investment Conference
GAITHERSBURG, Md., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced that Bill Enright, President and Chief Executive Officer ...
September 6, 2017
Catalyst Biosciences Announces Positive Factor IX Clinical Data
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (CBIO), today announced positive clinical data from the first Cohort of its ...
September 6, 2017
Arena Pharmaceuticals to Present Additional Pre-Clinical Data on Ralinepag for Treatment of Pulmonary Arterial Hypertension at International Congress of the European Respiratory Society
SAN DIEGO, Sept. 6, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) will present additional detailed pre-clinical pharmacology and pharmacokinetic data on ralinepag (APD811), the Company's next-generation, ...
September 6, 2017
UroGen Pharma Strengthens Management Team with the Appointment of Paul Chu as Vice President of Business Development
RA'ANANA, Israel, and NEW YORK, Sept. 06, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs ...
September 6, 2017
Rexahn Pharmaceuticals to Present at 19th Annual Rodman & Renshaw Global Investment Conference
ROCKVILLE, Md., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, ...
September 6, 2017
Mateon Therapeutics to Present at the 19th Annual Rodman and Renshaw Global Investment Conference on September 12, 2017
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (MATN), a biopharmaceutical company developing vascular disrupting agents for the treatment of ...
September 6, 2017
DelMar Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference on September 10-12, 2017
VANCOUVER, British Columbia and MENLO PARK, Calif., Sept. 6, 2017 /PRNewswire/ -- DelMar Pharmaceuticals (DMPI) ("DelMar" and "the Company"), a biopharmaceutical company focused on the development ...
September 6, 2017
Sitravatinib Data To Be Highlighted At The IASLC 18th World Conference on Lung Cancer
Mirati Therapeutics, Inc. (MRTX), a clinical stage targeted oncology biotechnology company, will highlight data on sitravatinib at the IASLC 18th World Conference on Lung Cancer ...
September 6, 2017
Molecular Templates to Present at the BioCentury 24th Annual Newsmakers in the Biotech Industry Conference
AUSTIN, Texas, Sept. 06, 2017 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered ...
September 6, 2017
LifeSci Advisors Announces 10th Board Appointment Through Board Placement Initiative
NEW YORK, Sept. 06, 2017 (GLOBE NEWSWIRE) --  LifeSci Advisors, an investor relations and corporate communications firm focused on the life sciences sector, announced today ...
September 5, 2017
Soleno Therapeutics Announces CFO Transition
REDWOOD CITY, Calif., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare ...
September 5, 2017
Kiadis Pharma Appoints Karl Hård as Head of Investor Relations and Communications
Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative products to make bone marrow ...
Page 94 of 117